The Natural History of Genital Human Papillomavirus Among HIV-Negative Men Having Sex With Men and Men Having Sex With Women
Carregando...
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
OXFORD UNIV PRESS INC
Autores
NYITRAY, Alan G.
CHANG, Mihyun
ABRAHAMSEN, Martha
PAPENFUSS, Mary
QUITERIO, Manuel
SALMERON, Jorge
LAZCANO-PONCE, Eduardo
Citação
JOURNAL OF INFECTIOUS DISEASES, v.212, n.2, p.202-212, 2015
Resumo
Background. Although human immunodeficiency virus (HIV)-negative men having sex with men (MSM) bear a substantial burden of human papillomavirus (HPV)-associated disease, prospective studies of genital HPV infection in this population are scarce. Methods. HPV genotyping was conducted on genital samples from men (aged 18-70 years) from Brazil, Mexico, or the United States who provided specimens at 6-month intervals for up to 4 years. Eligibility criteria included no history of genital warts or HIV infection. Evaluable specimens were collected from 564 MSM and 3029 men having sex with women (MSW). Incidence and clearance estimates with 95% confidence intervals were calculated. Results. The 12-month cumulative incidence of genital HPV was high in both MSM (25%; 95% confidence interval, 21%-30%) and MSW (21%; 20%-23%). After stratifying by city, MSM and MSW incidence rates were comparable, with 3 exceptions where MSM had higher incidence in >= 1 city: the group of quadrivalent vaccine types, HPV-45, and HPV-11. Median times to HPV-16 clearance were also comparable, with point estimates of >6 months for both MSM and MSW. Conclusions. Unlike with many other sexually transmitted infections, genital HPV natural history may be similar in HIV-negative MSM and MSW. Study periods of <= 6 months, however, may not be long enough to accurately measure the persistence of these infections in men.
Palavras-chave
HPV, men, incidence, clearance, duration, epidemiology, MSM, bisexual men, heterosexual men
Referências
- Bleeker MCG, 2009, WORLD J UROL, V27, P141, DOI 10.1007/s00345-008-0302-z
- Bouvard V, 2009, LANCET ONCOL, V10, P321
- Centers for Disease Control and Prevention, 2014, SEX TRANSM DIS SURV
- Chaturvedi AK, 2010, J ADOLESCENT HEALTH, V46, pS20, DOI 10.1016/j.jadohealth.2010.01.016
- DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988
- Darwich L, 2013, SEX TRANSM DIS, V40, P611, DOI 10.1097/01.OLQ.0000430798.61475.08
- Gil-Prieto Ruth, 2012, Hum Vaccin Immunother, V8, P201, DOI 10.4161/hv.18388
- Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151
- Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
- Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
- Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020
- Hartwig S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-30
- Hernandez BY, 2008, EMERG INFECT DIS, V14, P888, DOI 10.3201/eid1406.070616
- LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085
- Llata E, 2014, SEX TRANSM DIS, V41, P89, DOI 10.1097/OLQ.0000000000000077
- Lu BB, 2012, CANCER EPIDEM BIOMAR, V21, P1542, DOI 10.1158/1055-9965.EPI-12-0483
- Nyitray AG, 2011, J INFECT DIS, V203, P49, DOI 10.1093/infdis/jiq021
- Nyitray AG, 2011, SEX TRANSM DIS, V38, P932, DOI 10.1097/OLQ.0b013e31822154f9
- Patel H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-39
- Robinson D, 2009, BRIT J CANCER, V100, P527, DOI 10.1038/sj.bjc.6604871
- Savin-Williams RC, 2007, ARCH SEX BEHAV, V36, P385, DOI 10.1007/s10508-006-9088-5
- Silva RJC, 2011, J MED VIROL, V83, P127, DOI 10.1002/jmv.21950
- Syrjanen K, 2007, EUR J GYNAECOL ONCOL, V28, P337
- Vandepapeliere P, 2005, J INFECT DIS, V192, P2099, DOI 10.1086/498164
- Van Poppel H, 2013, ANN ONCOL, V24, P115, DOI 10.1093/annonc/mdt286
- Vriend HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060696
- Woodhall SC, 2009, SEX TRANSM DIS, V36, P515, DOI 10.1097/OLQ.0b013e3181a74c2c